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Background: The Androgen Deficiency in Aging Male (ADAM) questionnaire is increasingly popular for evaluation of androgen 
deficiency (AD) in sub-Saharan African men with type 2 diabetes mellitus (DM). However, its reliability in this population is 
unknown.
Methods: Total testosterone  <  8  nmol/L was used as the gold standard for diagnosis of AD in this cross-sectional survey of 
200 type 2 DM males aged 30–69 years. Participants also completed the Saint Louis University ADAM questionnaire whereby 
AD was diagnosed by a ‘yes’ answer to question 1 (reduced libido) or 7 (erectile dysfunction) or any other three questions. The 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall accuracy of the ADAM tool 
were computed.
Results: The mean age of the participants was 58.0 ± 8.8 years. A total of 142 subjects (71.0%) had AD based on the ADAM 
questionnaire. However, AD was biochemically confirmed in 59 subjects (29.5%). The ADAM questionnaire rendered a sensitivity 
of 88.1%, specificity of 44.7%, PPV of 50.0%, NPV of 85.7% and accuracy of 61.4%.
Conclusion: Despite an impressive sensitivity, the low specificity and overall accuracy of the ADAM questionnaire makes it 
unreliable for the detection of AD in sub-Saharan African men with type 2 DM.
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Introduction
Age-related androgen deficiency (AD) in males is well recognised 
in the literature.1,2 It is estimated that testosterone declines at a 
rate of about 0.5–2% per year during normal ageing, starting 
from the fifth decade.1 Type 2 diabetes mellitus (DM) is 
independently associated with testosterone deficiency, and 
accelerates the age-related decline in androgens that naturally 
accompanies the ageing process.3,4
Androgen deficiency is known to be associated with several 
adverse consequences including sexual disorders, mood 
changes (irritability and depression), cognitive decline, reduced 
muscle and bone mass leading to increased fracture risk, poor 
quality of life and mortality.5–7 Therefore AD constitutes an 
additional substantial burden in persons with diabetes. More 
recently, male androgen deficiency has been recognised as an 
independent risk factor for coronary artery disease.8 These 
underscore the need for prompt detection and treatment of this 
condition.
Although measurement of serum testosterone has been the 
gold standard for the diagnosis of AD, testosterone assays are 
not readily available, especially in resource-poor settings with 
inadequate healthcare facilities. Consequently, efforts have been 
made to develop and validate simple screening questionnaires 
for the clinical detection of AD.9–11 These questionnaires are often 
based on symptom complexes that are known to be associated 
with low testosterone concentrations.
Of all the available screening questionnaires for AD, the Saint 
Louis University Androgen Deficiency in Aging Male (ADAM) 
questionnaire is the most widely used.9 Although it was originally 
developed in a non-diabetic Caucasian population, the ADAM 
questionnaire is widely used in Africans and diabetics despite 
absence of evidence of its reliability in this population.12,13 This 
study was aimed at evaluating the accuracy of the ADAM 
questionnaire as a tool for clinical detection of AD in sub-Saharan 
African men with type 2 DM.
Subjects and methods
Males aged 30–69 years diagnosed with type 2 DM were included 
in this cross-sectional survey. Participants were purposely and 
consecutively recruited from the diabetes clinic of Obafemi 
Awolowo University Teaching Hospital, Ile-Ife, Nigeria. The 
hospital’s Research and Ethics Committee approved the protocol 
while each patient gave written consent. Exclusion criteria were 
previous/current therapy with androgens or androgen 
antagonists, acute febrile illness in the last one week, known or 
suspected chronic debilitating illnesses including chronic heart 
failure, chronic liver disease, chronic renal failure, tuberculosis, 
chronic obstructive pulmonary diseases, acquired 
immunodeficiency syndrome and malignancy. Relevant socio-
demographic and diabetes-related information were 
documented.
Clinical evaluation of androgen deficiency
Participants completed the original version of the ADAM 
questionnaire.9 It consists of 10 items describing the most 
common symptoms observed in persons with AD and covers 
three dimensions, i.e. energy, mood and sexual disorders. A 
positive ADAM test is made if the participant answers ‘yes’ to any 
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of the sexual questions (decreases in libido or strength of 
erections) or any other three questions.
Laboratory evaluation
Venous blood samples were drawn between 8.00 and 10.00 a.m. 
in a plain specimen bottle on the day of screening. The clotted 
specimen was centrifuged at 3000 revolutions per minute for 5 
minutes and the serum extracted and frozen. It was used for 
measurement of total testosterone (TT) by enzyme-linked 
immunosorbent assay technique (Fortress Diagnostics, Antrim, 
UK). Diagnosis of AD was based on the joint clinical practice 
guideline of the International Society of Andrology, International 
Society for the Study of Aging Male and the European Urology 
Association, which defined AD as TT < 8 nmol/l.14
Statistical analysis
Analysis was done with Statistical Package for Social Sciences® 
software (version 17.0; SPSS Inc. Chicago, IL, USA). Data were 
expressed as means  ±  standard deviations (SD) or frequencies 
and percentages as appropriate. Differences between categorical 
variables were tested by chi-square while an independent t-test 
and ANOVA were employed for continuous variables as 
appropriate. The sensitivity (the probability that a patient with 
TT < 8 nmol/L has a positive ADAM test), specificity (the probability 
that a patient with TT  >  8  nmol/L has a negative ADAM test), 
positive predictive value (PPV) (the probability that a patient with 
a positive ADAM test has TT < 8 nmol/L) and negative predictive 
value (NPV) (the probability that a patient with a negative ADAM 
test has TT  >  8  nmol/L) of the ADAM questionnaire were 
determined. The overall efficiency of ADAM, which was defined 
by the percentage of subjects who were correctly classified as 
either hypogonadal or normal, was also determined. Similar 
calculations were also independently determined for the items in 
the sexual domain of the ADAM questionnaire (items 1 and 7). 
Statistical significance was established at p < 0.05.
Results
A total of 200 participants with a mean age of 58.0 ± 8.8 years (range 
30–69  years) completed the study. Based on the ADAM 
questionnaire, 142 subjects (71.0%) had androgen deficiency and 
this frequency increased significantly with increasing age (Table 1).
Using TT < 8 nmol/L, AD was confirmed in 59 (29.5%) subjects. 
Testosterone levels progressively declined with age, from 
21.5 ± 7.5 nmol/L in the age range 30–39 years to 11.8 ±  6.7 nmol/L 
in the age range 60–69 years. Compared with subjects in the age 
range 30–39 years, TT declined to about 91.1% in the age category 
40–49 years, 72.7% in the age category 50–59 years and 55.1% in 
the age group 60–69  years and this trend was statistically 
significant (ANOVA, p < 0.001) (Table 2).
Testosterone levels were compared according to the presence or 
absence of the symptoms of androgen deficiency as contained in 
the ADAM questionnaire. As shown in Table 3, TT did not differ 
significantly between those who had and those who did not have 
most of the symptoms. Exceptions are reduced libido (11.0 ± 7.7 
vs. 16.7 ± 7.4, p < 0.001), lack of energy (11.1 ± 6.1 vs. 16.6 ± 8.4, 
p < 0.001), grumpiness (11.4 ± 8.0 vs. 15.2 ± 7.8, p = 0.005) and 
erectile dysfunction (12.0 ± 7.2 vs. 18.2 ± 7.8, p < 0.001).
The ADAM questionnaire rendered a sensitivity of 88.1%, 
specificity of 44.7%, PPV of 50.0%, NPV of 85.7% and overall 
accuracy of 61.4% (Table 4). As shown, each item in the sexual 
domain (items 1 and 7) showed better diagnostic performance 
than the complete ADAM questionnaire although they both 
demonstrated lower sensitivities. Reduced libido had the highest 
specificity of 75.5%, PPV of 64.1% and accuracy of 73.2%.
Discussion
It is now well established that androgen deficiency frequently 
complicates type 2 diabetes.3,4,12 Although the exact 
pathophysiological mechanism remains poorly understood, 
hypothalamic insulin resistance has largely been blamed for this 
abnormality.14,15 Type 2 DM is also more prevalent in the older 
populations in whom age-related decline in serum testosterone 
notably occurs. The Endocrine Society recommends routine 
screening of all men with type 2 DM for AD due to the high 
frequency of this condition in this group of patients.16
Table 1. Prevalence of androgen deficiency symptoms according to age
Notes: Chi-square = 9.175, p = 0.027.
Age group (years) ADAM
Positive, n (%) Negative, n (%)
30–39 4 (2.8) 6 (10.3)
40–49 15 (10.6) 10 (17.2)
50–59 40 (28.2) 19 (32.8)
60–69 83 (58.5) 23 (39.7)




n TT (mean  
± SD)
% Change F p-value
30–39 10 21.5 ± 7.5 Reference 11.868 < 0.001
40–49 25 19.5 ± 8.9 91.1
50–59 59 15.6 ± 7.9 72.7
60–69 106 11.8 ± 6.7 55.1
Table 3. Testosterone levels of subjects with and without symptoms of 
androgen deficiency in the ADAM questionnaire
Notes: Data are mean ± SD. TT = total testosterone.
ADAM symptom TT (nmol/L) t p-value
Yes No
Decreased libido 11.0 ± 7.7 16.7 ± 7.4 5.263 < 0.001
Lack of energy 11.1 ± 6.1 16.6 ± 8.4 5.063 < 0.001
Decrease in strength/
endurance 15.3 ± 8.2 13.9 ± 7.9 1.214 0.226
Lost height 10.2 ± 5.6 14.6 ± 8.0 1.617 0.107
Decreased enjoyment 
of life 13.3 ± 7.6 15.1 ± 8.2 1.521 0.130
Often sad or grumpy 11.4 ± 8.0 15.2 ± 7.8 2.817 0.005
Erectile dysfunction 12.0 ± 7.2 18.2 ± 7.8 5.719 < 0.001
Recent deterioration in 
sporting ability 13.3 ± 7.4 14.9 ± 8.2 1.181 0.239
Falling asleep quickly 
after dinner 14.0 ± 7.8 14.7 ± 8.2 0.632 0.528
Recent deterioration in 
work performance 16.7 ± 9.2 14.0 ± 7.8 1.628 0.105
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In resource-poor settings such as sub-Saharan Africa, routine 
testosterone assays in men diagnosed with type 2 DM is not 
feasible. Therefore, the availability of a cheap, user-friendly and 
yet reliable clinical instrument for the detection of AD in diabetic 
men would be of immense benefit. The Androgen Deficiency in 
Aging Male questionnaire is widely used in Africa but its reliability 
has not been established.
In this cross-sectional survey, we evaluated the usefulness of the 
ADAM tool for the detection of AD in a population of mostly 
middle-aged and elderly Nigerian men with type 2 DM. With a 
diagnostic accuracy of 61.4%, the ADAM questionnaire 
misclassified nearly 40% of subjects in whom it was applied, 
making it an unreliable tool for the identification of AD in this 
group of patients. Although the ADAM instrument demonstrated 
a satisfactory sensitivity of 88.1%, its low specificity of 47% 
suggests that it cannot be used as a surrogate for biochemical 
determination of serum testosterone in evaluation of AD in type 2 
diabetic males. This poor performance of the ADAM questionnaire 
has been reported by many authors in different patient 
populations. For instance, Chu et al.,17 in a study of nearly 800 
non-diabetic Chinese men aged 18–89 years who were screened 
for AD using the ADAM questionnaire, reported a similarly high 
sensitivity of 86% and low specificity of 40% based on bioavailable 
testosterone (BT). The PPV and NPV of 50% and 85.7% respectively 
that were observed in this study were similar to those reported in 
the said study (46% and 82% respectively). A previous large 
Belgian study involving over 5000 subjects aged 50–70  years, 
which defined AD based on free testosterone (FT) level < 7 ng/dl, 
had observed a similar sensitivity of 81% for the ADAM 
instrument.18 However, it also reported a much lower specificity of 
21.6% and concluded that the ADAM questionnaire lacked 
adequate specificity to be relied on for the detection of AD. 
Morley et al.19 in the United States observed similar trends 
regarding the ADAM questionnaire, reporting a high sensitivity of 
97% and low specificity of 30%. Recently, some Taiwanese 
researchers evaluated the performance of two popular screening 
questionnaires—the ADAM and the Aging Males Symptoms 
(AMS) scale—in a cohort of middle-aged men.20 Like our study, 
total testosterone was used to define AD. The authors reported an 
even lower sensitivity of 72%, specificity of 26.5%, PPV of 21.8% 
and NPV of 76%. This lower sensitivity may be due to the higher 
testosterone cut-off value of 10.4  nmol/L used to define AD in 
that study compared with 8.0 nmol/L as used in our study.
It is noteworthy that all the cited studies were conducted among 
non-diabetic populations. To our knowledge, there are no 
published data on the reliability of the ADAM questionnaire 
specifically in diabetic subjects elsewhere. Interestingly, our 
findings did not differ significantly from those of other authors, 
and confirm earlier reports on the disappointing performance of 
the ADAM tool. Our findings also suggest that the ADAM 
questionnaire did not discriminate between diabetics and non-
diabetics.
The ADAM questionnaire evaluates three main domains, namely, 
energy, mood and sexual function. A critical look at these domains 
shows that they are prone to being affected by several other 
illnesses besides androgen deficiency. Therefore, the poor 
specificity of the ADAM instrument is not surprising. This is even 
more so in persons with diabetes such as our study population in 
whom disorders of energy, mood and sexuality are common even 
in the presence of normal circulating androgen concentrations 
and could be accounted for by hyper/hypoglycaemia, 
cardiovascular and renal diseases, adverse effects of medications 
and psychological problems including anxiety and depression. 
For instance, the prevalence of clinically significant depression 
among Nigerians with DM has been reported to be as high as 
30%.21 Similarly, erectile dysfunction is a common complication of 
DM, occurring in over 70% of men with type 2 DM.22 Therefore, it 
is deducible that the non-specific nature of the components of 
the ADAM questionnaire may be responsible for its poor overall 
efficiency in identifying male androgen deficiency.
Findings from this study suggest that the sexual domain of ADAM 
alone may be more reliable than the complete questionnaire. We 
observed that reduced libido alone had a reasonably higher 
specificity of 75.5% and overall accuracy of 73.2% compared with 
44.7% and 61.4% respectively demonstrated by the complete 
ADAM questionnaire (see Table 4). Similarly, erectile dysfunction 
alone had a better specificity and accuracy of 53.2% and 63.4% 
respectively compared with the complete questionnaire. 
Furthermore, subjects who answered ‘yes’ to the two questions in 
the sexual domain (items 1 and 7) had significantly lower 
testosterone concentrations than those who answered ‘no’ (p < 0.001 
respectively). Blumel et al.23 had also reported better performance of 
the sexual items of the ADAM instrument than the complete 
questionnaire and attributed this finding to the high prevalence of 
psychological symptoms in the complete questionnaire, which are 
Table 4: Diagnostic efficiency of the ADAM questionnaire and its sexual domain
Notes: TT = total testosterone, PPV = positive predictive value, NPV = negative predictive value.
TT Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Low Normal
ADAM
Positive 52 52 88.1 44.7 50.0 85.7 61.4
Negative 7 42
Reduced libido
Yes 41 23 69.4 75.5 64.1 79.8 73.2
No 18 71
Erectile dysfunction
Yes 47 44 79.7 53.2 51.6 80.6 63.4
No          12              50
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highly non-specific. With a uniformly high NPV of over 80% observed 
in both our study and those of other authors,17–20 it appears that the 
most important usefulness of the ADAM test is the identification of 
subjects in whom further evaluation by biochemical testing is 
unwarranted. This suggests that a negative ADAM test is more useful 
than a positive one in clinical practice.
In conclusion, despite having satisfactory sensitivity, the low 
specificity and poor overall accuracy of the ADAM questionnaire 
in this study means it cannot be used as a surrogate for 
biochemical assay of testosterone in the detection of androgen 
deficiency in sub-Saharan African men with type 2 DM. Owing to 
scarce healthcare resources in our setting, we recommend that 
sub-Saharan African men with type 2 DM in whom clinical 
suspicion of AD exists should be initially screened with the ADAM 
instrument and those who test negative may not undergo further 
testing while those who test positive should have testosterone 
measurement to confirm their androgen status. Furthermore, the 
presence of reduced libido should be considered a high risk factor 
for AD requiring proper evaluation in view of the close association 
between low libido and AD, as well as its high specificity in 
detecting androgen deficiency.
The limitations of this study need to be highlighted. First, free or 
bioavailable testosterone would be more accurate in evaluating 
AD than total testosterone as used in this study since the former 
represents the biologically active testosterone fraction. An 
alternative would have been to measure sex hormone binding 
globulin and albumin to calculate free testosterone index. 
However, this could not be done owing to cost constraints. 
Furthermore, the small sample size means that the findings in this 
study should be interpreted with caution and may not be 
generalised to black sub-Saharan African men with type 2 DM.
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